Search Results - "Thoma, B."

Refine Results
  1. 1
  2. 2

    A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years by Schwarz, T.F, Flamaing, J, Rümke, H.C, Penzes, J, Juergens, C, Wenz, A, Jayawardene, D, Giardina, P, Emini, E.A, Gruber, W.C, Schmoele-Thoma, B

    Published in Vaccine (18-07-2011)
    “…Abstract This randomized, double-blind study evaluated concomitant administration of 13-valent pneumococcal conjugate vaccine (PCV13) and trivalent inactivated…”
    Get full text
    Journal Article
  3. 3

    A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy by Moore, JN, Healy, JR, Thoma, BN, Peahota, MM, Ahamadi, M, Schmidt, L, Cavarocchi, NC, Kraft, WK

    “…The literature on the pharmacokinetics of vancomycin in patients undergoing extracorporeal membrane oxygenation (ECMO) therapy is sparse. A population…”
    Get full text
    Journal Article
  4. 4

    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18–49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine by Bryant, K.A, Frenck, R, Gurtman, A, Rubino, J, Treanor, J, Thompson, A, Jones, T.R, Sundaraiyer, V, Baxter, L.M, Gruber, W.C, Emini, E.A, Scott, D.A, Schmoele-Thoma, B

    Published in Vaccine (26-10-2015)
    “…Highlights • PCV13 was immunogenic and well tolerated in adults of all ages. • Functional antibody titers were generally higher in adults 18–49 vs 60–64 years…”
    Get full text
    Journal Article
  5. 5

    Rationale and design of CAPITA : a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults by HAK, E, GROBBEE, D. E, PATTERSON, S, VAN ALPHEN, A. J, BONTEN, M. J. M, SANDERS, E. A. M, VERHEIJ, T. J. M, BOLKENBAAS, M, HUIJTS, S. M, GRUBER, W. C, TANSEY, S, MCDONOUGH, A, THOMA, B

    Published in Netherlands journal of medicine (01-10-2008)
    “…The burden of community-acquired pneumonia (CAP) among the elderly is high and has increased over the last decades. Streptococcus pneumoniae is the most common…”
    Get full text
    Journal Article
  6. 6

    Atypical Cowpox Virus Infection in a Series of Cats by Jungwirth, N., Puff, C., Köster, K., Mischke, R., Meyer, H., Stark, A., Thoma, B., Zöller, G., Seehusen, F., Hewicker-Trautwein, M., Beineke, A., Baumgärtner, W., Wohlsein, P.

    Published in Journal of comparative pathology (01-01-2018)
    “…Within 4 weeks, five cats with skin lesions affecting the hindlimbs and mainly consisting of oedema, hyperaemia and plaque-like alterations were presented to…”
    Get full text
    Journal Article
  7. 7

    Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1×, 2×, or 4×) in healthy subjects aged 70 years or older by Lode, H, Schmoele-Thoma, B, Gruber, W, Ahlers, N, Fernsten, P, Baker, S, Razmpour, A, Siber, G, Hackell, J, Lockhart, S, Burkhardt, O, Welte, T, de Roux, A

    Published in Vaccine (12-07-2011)
    “…Abstract Healthy adults aged ≥70 years ( N = 443) with no history of pneumococcal vaccination received 7- or 9-valent pneumococcal conjugate vaccine (PCV7 or…”
    Get full text
    Journal Article
  8. 8

    The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine by Schmitt, H.J, Faber, J, Lorenz, I, Schmöle-Thoma, B, Ahlers, N

    Published in Vaccine (08-09-2003)
    “…To evaluate immune responses, safety and reactogenicity of the concomitant use of DTaP-IPV-Hib and the newly available 7-valent pneumococcal conjugate (7VPnC)…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes by Thoma, B, Bird, T A, Friend, D J, Gearing, D P, Dower, S K

    Published in The Journal of biological chemistry (25-02-1994)
    “…Leukemia inhibitory factor (LIF) and oncostatin M (OSM) both bind to the same receptor with high affinity and thus mediate an overlapping spectrum of…”
    Get full text
    Journal Article
  11. 11

    Prevalence of weight gain in patients with better renal transplant function by Thoma, B, Grover, V K, Shoker, A

    Published in Clinical nephrology (01-06-2006)
    “…This study investigates the association between renal function and change in weight after kidney transplantation. Retrospective analyses of 165 transplant…”
    Get more information
    Journal Article
  12. 12

    Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death by Ware, C B, Horowitz, M C, Renshaw, B R, Hunt, J S, Liggitt, D, Koblar, S A, Gliniak, B C, McKenna, H J, Papayannopoulou, T, Thoma, B

    Published in Development (Cambridge) (01-05-1995)
    “…The low-affinity receptor for leukemia inhibitory factor (LIFR) interacts with gp130 to induce an intracellular signal cascade. The LIFR-gp130 heterodimer is…”
    Get full text
    Journal Article
  13. 13

    Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha- mediated enhancement of T cell responses by Scheurich, P, Thoma, B, Ucer, U, Pfizenmaier, K

    Published in The Journal of immunology (1950) (15-03-1987)
    “…The expression of specific tumor necrosis factor (TNF) membrane receptors and biological effects of recombinant TNF (rTNF)-alpha on normal human T lymphocytes…”
    Get full text
    Journal Article
  14. 14

    Development of the cytodetachment technique to quantify mechanical adhesiveness of the single cell by Athanasiou, K.A, Thoma, B.S, Lanctot, D.R, Shin, D, Agrawal, C.M, LeBaron, R.G

    Published in Biomaterials (01-12-1999)
    “…Adhesion of cells to biomaterials or to components of the extracellular matrix is fundamental in many tissue engineering and biotechnological processes, as…”
    Get full text
    Journal Article
  15. 15

    Human XPC-hHR23B interacts with XPA-RPA in the recognition of triplex-directed psoralen DNA interstrand crosslinks by Thoma, Brian S., Wakasugi, Mitsuo, Christensen, Jesper, Reddy, Madhava C., Vasquez, Karen M.

    Published in Nucleic acids research (01-01-2005)
    “…DNA interstrand crosslinks (ICLs) represent a severe form of damage that blocks DNA metabolic processes and can lead to cell death or carcinogenesis. The…”
    Get full text
    Journal Article
  16. 16

    Critical DNA damage recognition functions of XPC-hHR23B and XPA-RPA in nucleotide excision repair by Thoma, Brian S., Vasquez, Karen M.

    Published in Molecular carcinogenesis (01-09-2003)
    “…It has been reported that 80–90% of human cancers may result, in part, from DNA damage. Cell survival depends critically on the stability of our DNA and…”
    Get full text
    Journal Article
  17. 17

    Change in Diuretic Dose After Initiation of a SGLT2 Inhibitor in Patients with Heart Failure with Reduced Ejection Fraction by Wildemann, R., Karalis, D.G., Mirachi, N., Thoma, B., D'Angelo, R.

    “…This study was designed to evaluate the change in loop diuretic dose at three months post-initiation of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) in…”
    Get full text
    Journal Article
  18. 18
  19. 19

    The clinical learning environment by Nordquist, Jonas, Hall, Jena, Caverzagie, Kelly, Snell, Linda, Chan, Ming-Ka, Thoma, Brent, Razack, Saleem, Philibert, Ingrid

    Published in Medical teacher (01-04-2019)
    “…Learning in a clinical context is foundational in the training of health professionals; there is simply no alternative. The subject of the clinical learning…”
    Get full text
    Journal Article
  20. 20